Naphazoline + Pheniramine

Ophthalmic
Allergic condition, ocular, Inflammatory condition, ocular

Narrow-angle glaucoma.

Patient with CV disease, hypertension, diabetes mellitus, hyperthyroidism, benign prostatic hyperplasia, local infection or injury. Children and elderly. Pregnancy and lactation. Concomitant use with MAOIs.

Significant: Eye irritation, light sensitivity (temporary), tingling sensation, rebound ocular vasodilation or congestion (prolonged or excessive use).
Eye disorders: Ocular discomfort, pupil dilatation, increased ocular pressure, mydriasis, keratitis, eye pain, ocular hyperaemia, mydriasis, blurred vision (temporary).

Ophth: C

This drug may cause transient effect on vision, if affected, do not drive or operate machinery. Remove contact lenses prior to administration and reinsert after 15 minutes.

Symptoms (particularly in children): Depression of the CNS with marked reduction in body temperature and bradycardia, excessive sweating, drowsiness, and coma; hypertension followed by hypotension. Management: Symptomatic and supportive treatment.

Increased risk of severe hypertensive crisis with MAOIs. Enhanced therapeutic effect with TCAs.

Description: Naphazoline is an α-adrenergic receptor agonist which causes vasoconstriction by stimulating arterioles of the conjunctiva thus reducing swelling, redness and discomfort.
Pheniramine is an alkylamine derivative which binds to histamine H₁ receptors on conjunctival epithelial cells, thereby reducing ocular itching.
Onset: Conjunctival vasoconstriction: Within 10 minutes.
Duration: Up to 6 hours.
Pharmacokinetics:
Absorption: Pheniramine: Time to peak plasma concentration: 1-2.5 hours.
Metabolism: Pheniramine: Metabolised to N-desmethylpheniramine, and N-didesmethylpheniramine metabolites.
Excretion: Pheniramine: Via urine (70-83% as unchanged drug and metabolites). Elimination half-life: 16-19 hours.

Source: National Center for Biotechnology Information. PubChem Database. Naphazoline, CID=4436, https://pubchem.ncbi.nlm.nih.gov/compound/Naphazoline (accessed on Jan. 22, 2020)

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 4761, Pheniramine. https://pubchem.ncbi.nlm.nih.gov/compound/Pheniramine. Accessed Sept. 24, 2021.

Store between 15-25°C. Protect from light.

Ophthalmic Decongestants, Anesthetics, Anti-Inflammatories

S01GA51 - naphazoline, combinations ; Belongs to the class of sympathomimetics used as ophthalmologic decongestants.

Anon. Naphazoline (Ophthalmic). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 12/08/2021.

Anon. Naphazoline and Pheniramine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 12/08/2021.

Anon. Pheniramine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 12/08/2021.

Buckingham R (ed). Naphazoline. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/08/2021.

Buckingham R (ed). Pheniramine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/08/2021.

Celsus Naphazoline Hydrochloride + Pheniramine Maleate (Celsus Pharmaceuticals Phils., Inc.). MIMS Philippines. http://www.mims.com/philippines. Accessed 12/08/2021.

Naphazoline; Pheniramine. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 12/08/2021.

Naphcon A (Alcon Laboratories, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 12/08/2021.

Naphcon A (S.A. Alcon-Couvreur N.V.). MIMS Philippines. http://www.mims.com/philippines. Accessed 12/08/2021.

Opcon-A (Bausch & Lomb Incorporated). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 12/08/2021.

Visine Allergy Eye Relief Multi-Action (Johnson & Johnson Consumer Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 12/08/2021.